You are here

  • Home
  • Archive
  • Volume 18, Issue 2
  • Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary

Article Text

Article menu
Download PDFPDF
CORRESPONDENCE AND BRIEF REPORT
Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary
  1. A. Jaishuen*,†,
  2. J. P. Berrios-Rivera‡,
  3. N. Sirisabya*,
  4. H. G. Zheng*,
  5. Y. Li* and
  6. J. J. Kavanagh*
  1. * Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas;
  2. † Department of Obstetrics and Gynecology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; and
  3. ‡ Rheumatology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
  1. Address correspondence and reprint requests to: John J. Kavanagh, MD, Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Unit 1362, Houston, TX 77030-1439, USA. Email: jkavanag{at}mdanderson.org

Abstract

Bevacizumab (BVC) is currently used in recurrent ovarian cancer and as part of the initial treatment for ovarian cancer. The most serious toxicities associated with BVC include gastrointestinal perforations, delayed wound healing, and hemorrhage. Arthritis had never been addressed in patients who received BVC treatment. This is the first case report of arthritis emergence linked to BVC administration. A 59-year-old female with recurrent ovarian cancer received multiple hormonal and cytotoxic regimens for 5 years and then developed erosive osteoarthritis of the hands secondary to BVC and paclitaxel. This effect was confirmed by a significant improvement in her symptoms and signs, after treatment was discontinued.

  • arthritis
  • bevacizumab
  • ovarian cancer
  • vascular endothelial growth factor

https://doi.org/10.1111/j.1525-1438.2007.01023.x

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.